These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 34394274)

  • 1. The efficacy of dapagliflozin for type 1 diabetes: a meta-analysis of randomized controlled studies.
    Ma J; Zhao Y; Fan H; Liu J
    Afr Health Sci; 2021 Mar; 21(1):1-7. PubMed ID: 34394274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of dapagliflozin as monotherapy in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
    Feng M; Lv H; Xu X; Wang J; Lyu W; Fu S
    Medicine (Baltimore); 2019 Jul; 98(30):e16575. PubMed ID: 31348290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A systematic review and dose-response meta-analysis on the efficacy of dapagliflozin in patients with type 1 diabetes mellitus.
    Abu-Zaid A; Altowairqi AK; Dissanayaka T; Oganesyan A; Bhagavathul AS; Alhabeeb H; Baradhwan A; Alomar S; Tom S
    Pharmacol Res; 2021 Mar; 165():105456. PubMed ID: 33515709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of dapagliflozin plus saxagliptin vs monotherapy as added to metformin in patients with type 2 diabetes: A meta-analysis.
    Zhuang Y; Song J; Ying M; Li M
    Medicine (Baltimore); 2020 Jul; 99(30):e21409. PubMed ID: 32791755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic outcome of dapagliflozin in patients with type 2 diabetes and non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials.
    Hu C; Qu T; Li L; Huang Y; Liu H; Rao C
    Afr Health Sci; 2023 Jun; 23(2):416-421. PubMed ID: 38223613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis.
    Zaccardi F; Webb DR; Htike ZZ; Youssef D; Khunti K; Davies MJ
    Diabetes Obes Metab; 2016 Aug; 18(8):783-94. PubMed ID: 27059700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Dapagliflozin on Cardiovascular Events, Death, and Safety Outcomes in Patients with Heart Failure: A Meta-Analysis.
    Zheng XD; Qu Q; Jiang XY; Wang ZY; Tang C; Sun JY
    Am J Cardiovasc Drugs; 2021 May; 21(3):321-330. PubMed ID: 33001355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR).
    Fuchigami A; Shigiyama F; Kitazawa T; Okada Y; Ichijo T; Higa M; Hiyoshi T; Inoue I; Iso K; Yoshii H; Hirose T; Kumashiro N
    Cardiovasc Diabetol; 2020 Jan; 19(1):1. PubMed ID: 31910850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy of dapagliflozin combined with hypoglycaemic drugs in treating type 2 diabetes mellitus: meta-analysis of randomised controlled trials.
    Sun YN; Zhou Y; Chen X; Che WS; Leung SW
    BMJ Open; 2014 Apr; 4(4):e004619. PubMed ID: 24710132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.
    Zhang M; Zhang L; Wu B; Song H; An Z; Li S
    Diabetes Metab Res Rev; 2014 Mar; 30(3):204-21. PubMed ID: 24115369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease.
    Dekkers CCJ; Wheeler DC; Sjöström CD; Stefansson BV; Cain V; Heerspink HJL
    Nephrol Dial Transplant; 2018 Nov; 33(11):2005-2011. PubMed ID: 29370424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study.
    Weber MA; Mansfield TA; Cain VA; Iqbal N; Parikh S; Ptaszynska A
    Lancet Diabetes Endocrinol; 2016 Mar; 4(3):211-220. PubMed ID: 26620248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise.
    Kaku K; Kiyosue A; Inoue S; Ueda N; Tokudome T; Yang J; Langkilde AM
    Diabetes Obes Metab; 2014 Nov; 16(11):1102-10. PubMed ID: 24909293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials.
    Groop PH; Dandona P; Phillip M; Gillard P; Edelman S; Jendle J; Xu J; Scheerer MF; Thoren F; Iqbal N; Repetto E; Mathieu C
    Lancet Diabetes Endocrinol; 2020 Oct; 8(10):845-854. PubMed ID: 32946821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial.
    Mathieu C; Dandona P; Gillard P; Senior P; Hasslacher C; Araki E; Lind M; Bain SC; Jabbour S; Arya N; Hansen L; Thorén F; Langkilde AM;
    Diabetes Care; 2018 Sep; 41(9):1938-1946. PubMed ID: 30026335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucose Variables in Type 1 Diabetes Studies With Dapagliflozin: Pooled Analysis of Continuous Glucose Monitoring Data From DEPICT-1 and -2.
    Mathieu C; Dandona P; Phillip M; Oron T; Lind M; Hansen L; Thorén F; Xu J; Langkilde AM;
    Diabetes Care; 2019 Jun; 42(6):1081-1087. PubMed ID: 30967434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study.
    Dandona P; Mathieu C; Phillip M; Hansen L; Tschöpe D; Thorén F; Xu J; Langkilde AM;
    Diabetes Care; 2018 Dec; 41(12):2552-2559. PubMed ID: 30352894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study.
    Henry RR; Rosenstock J; Edelman S; Mudaliar S; Chalamandaris AG; Kasichayanula S; Bogle A; Iqbal N; List J; Griffen SC
    Diabetes Care; 2015 Mar; 38(3):412-9. PubMed ID: 25271207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of novel sodium glucose cotransporter-2 inhibitor remogliflozin in the management of type 2 diabetes mellitus: A systematic review and meta-analysis.
    Dutta D; Jindal R; Mehta D; Khandelwal D; Sharma M
    Diabetes Metab Syndr; 2021; 15(6):102315. PubMed ID: 34700292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dapagliflozin as add-on therapy in Asian patients with type 2 diabetes inadequately controlled on insulin with or without oral antihyperglycemic drugs: A randomized controlled trial.
    Yang W; Ma J; Li Y; Li Y; Zhou Z; Kim JH; Zhao J; Ptaszynska A
    J Diabetes; 2018 Jul; 10(7):589-599. PubMed ID: 29215189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.